Research programme: calcitonin gene-related peptide receptor antagonists - Biohaven Pharmaceutical Holding Company

Drug Profile

Research programme: calcitonin gene-related peptide receptor antagonists - Biohaven Pharmaceutical Holding Company

Alternative Names: BHV-3500

Latest Information Update: 27 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Biohaven Pharmaceutical Holding Company
  • Class Small molecules
  • Mechanism of Action Calcitonin gene-related peptide receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Migraine

Most Recent Events

  • 16 Jun 2017 Preclinical trials in Migraine (Prevention) in USA (PO) , (Biohaven pipeline, June 2017)
  • 16 Jun 2017 Biohaven announces intention to submit IND to the US FDA for Migraine (Prevention) in the second half of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top